GHRP-2 and growth hormone: separating signal from noise

What did @adamvanspanje actually say?

The creator describes GHRP-2 as a synthetic peptide that "stimulates your own natural growth hormone release from the pituitary" by "mimicking your own body's hormone rhythm." They credit it with potential to "improve recovery, fat metabolism and lean muscle growth" when combined with CJC-1295, and they do flag that some studies show elevated cortisol and prolactin as a concern.

That last part matters. A lot of peptide content on TikTok buries or omits the adverse signal entirely. Here, the creator named it. The framing is promotional, the account links directly to a clinic, and the educational disclaimer at the end does not change that context. But the basic biochemical description is not made up, so let's look at what the evidence actually says.

Does the science back this up?

Mostly, yes, with important caveats. GHRP-2 is a synthetic hexapeptide that acts as a ghrelin receptor agonist, stimulating GH secretion from the anterior pituitary in a pulsatile pattern. That mechanism is well-established in pharmacology literature. The pulsatile framing is accurate: unlike exogenous recombinant GH, GHRP-2 works through the body's own secretory machinery rather than replacing it.

The recovery and lean mass claims are where things get thinner. Studies in healthy adults are limited and largely short-duration. Khorram et al. (1997, Journal of Clinical Endocrinology and Metabolism) showed GHRP-2 significantly raised GH and IGF-1 in older adults, which is relevant to the age-related decline angle. Alba et al. (2004, JCEM) demonstrated additive GH release when GHRP-2 was combined with a GHRH analogue, supporting the stacking rationale. But neither study measured body composition or recovery outcomes directly. The jump from "raises GH" to "improves lean muscle and fat metabolism" is a reasonable hypothesis, not a proven outcome in humans.

What did they get wrong, or right?

The cortisol and prolactin flag is accurate and deserves credit. Multiple studies, including Ghigo et al. (1994, European Journal of Endocrinology), documented significant cortisol and prolactin rises alongside GH with GHRP-2 administration. The creator called it something "to be considered carefully," which is exactly the right level of caution. That is not nothing in this content space.

What the video gets wrong, or at least leaves dangerously vague, is the implied equivalence between preclinical and clinical evidence. The phrase "preclinical and limited clinical studies" is technically honest, but the surrounding language, "improve recovery, fat metabolism and lean muscle growth," presents these as probable outcomes rather than preliminary signals. Most human trials on GHRP-2 are short-term, small-sample, and not designed around the specific outcomes being advertised.

• The "natural rhythm" framing is reasonable but simplified. GHRP-2 also activates ghrelin pathways that have appetite and metabolic effects beyond GH release.
• No mention of the fact that GHRP-2 is not approved by the TGA for these uses, which matters for an Australian clinic account.
• The CJC-1295 combination is presented as a logical pairing without acknowledging that combined GHRH-GHRP stacks amplify GH release substantially, which also amplifies the cortisol and prolactin signal.

What should you actually know?

GHRP-2 stimulates GH release through a real, understood mechanism. The science is not fiction. But there is a significant distance between "stimulates GH secretion in research settings" and "improves your recovery and body composition," and that gap is where most of the risk lives. GH elevation is not automatically beneficial, and the cortisol co-elevation is a legitimate clinical concern, particularly for anyone using this for stress resilience or adrenal-adjacent goals.

If you are in Australia and seeing content from a clinic account, you should know that peptides like GHRP-2 occupy a complicated regulatory space. Many are not TGA-approved for routine use and are only legally available through specific compounding pathways. A video that ends with a clinic URL is not neutral education. That does not make the science wrong, but it does mean you should ask your own prescriber for a full risk picture before proceeding, not a TikTok account that has a financial stake in the conversation.